Have a feature idea you'd love to see implemented?
Let us know!
VYNE VYNE Therapeutics Inc
Price (delayed)
$2.69
Market cap
$39.68M
P/E Ratio
1.62
Dividend/share
N/A
EPS
$1.66
Enterprise value
$10.17M
VYNE's mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.
Highlights
VYNE's EPS has soared by 115% YoY
VYNE's debt is down by 19% since the previous quarter
VYNE Therapeutics's quick ratio has surged by 103% YoY but it has decreased by 46% QoQ
VYNE's equity is down by 10% since the previous quarter
Key stats
What are the main financial stats of VYNE
Market
Valuations
Earnings
Shares outstanding
14.75M
Market cap
$39.68M
Enterprise value
$10.17M
Price to earnings (P/E)
1.62
Price to book (P/B)
0.52
Price to sales (P/S)
235.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.92
Revenue
$486,000
EBIT
-$28.43M
EBITDA
-$28.43M
Free cash flow
-$26.75M
Per share
Balance sheet
Liquidity
EPS
$1.66
Free cash flow per share
-$0.63
Book value per share
$5.15
Revenue per share
$0.01
TBVPS
$2.03
Total assets
$86.65M
Total liabilities
$11.78M
Debt
$145,000
Equity
$74.87M
Working capital
$72.02M
Debt to equity
0
Current ratio
7.13
Quick ratio
6.65
Net debt/EBITDA
1.04
Margins
Efficiency
Dividend
EBITDA margin
-5,849.2%
Gross margin
100%
Net margin
-5,849.2%
Operating margin
-6,346.1%
Return on assets
-38.5%
Return on equity
-44%
Return on invested capital
-67.6%
Return on capital employed
-38%
Return on sales
-5,849.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VYNE stock price
How has the VYNE Therapeutics stock price performed over time
Intraday
13.5%
1 week
22.83%
1 month
46.2%
1 year
19.03%
YTD
15.45%
QTD
43.09%
Financial performance
How have VYNE Therapeutics's revenue and profit performed over time
Revenue
$486,000
Gross profit
$486,000
Operating income
-$30.84M
Net income
-$28.43M
Gross margin
100%
Net margin
-5,849.2%
VYNE's net margin is up by 32% year-on-year and by 15% since the previous quarter
VYNE's operating margin is up by 23% year-on-year and by 13% since the previous quarter
The net income has increased by 19% YoY and by 2.2% from the previous quarter
VYNE's gross profit is up by 19% YoY and by 15% QoQ
Growth
What is VYNE Therapeutics's growth rate over time
Valuation
What is VYNE Therapeutics stock price valuation
P/E
1.62
P/B
0.52
P/S
235.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.92
VYNE's EPS has soared by 115% YoY
VYNE's P/B is 74% below its 5-year quarterly average of 2.0 and 13% below its last 4 quarters average of 0.6
VYNE's equity is down by 10% since the previous quarter
VYNE's P/S is 64% above its last 4 quarters average of 143.9
The revenue is up by 19% year-on-year and by 15% since the previous quarter
Efficiency
How efficient is VYNE Therapeutics business performance
VYNE's return on invested capital has surged by 100% year-on-year and by 30% since the previous quarter
The ROE has soared by 64% YoY and by 24% QoQ
The ROA has soared by 59% YoY and by 23% from the previous quarter
VYNE's ROS is up by 32% YoY and by 15% QoQ
Dividends
What is VYNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VYNE.
Financial health
How did VYNE Therapeutics financials performed over time
VYNE Therapeutics's quick ratio has surged by 103% YoY but it has decreased by 46% QoQ
The current ratio has surged by 98% year-on-year but it has declined by 45% since the previous quarter
VYNE's debt is 100% smaller than its equity
VYNE's debt is down by 19% since the previous quarter
VYNE's equity is down by 10% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.